Biomarkers in amyotrophic lateral sclerosis

Turner, Martin R, Kiernan, Matthew C, Leigh, P Nigel and Talbot, Kevin (2009) Biomarkers in amyotrophic lateral sclerosis. Lancet Neurology, 8 (1). pp. 94-109. ISSN 1474-4422

Full text not available from this repository.

Abstract

Amyotrophic lateral sclerosis (ALS; motor neuron disease) is a relentlessly progressive disorder. After half a century of trials, only one drug with modest disease-modifying potency--riluzole--has been developed. The diagnosis of this disorder is still clinical and there is a pronounced delay between the onset of symptoms and diagnosis, possibly beyond the therapeutic window. Bedside quantification of the involvement of the corticospinal tract and extramotor areas is inadequate and functional rating scales, forced vital capacity, and patient survival have been the measures of therapeutic response so far. Potential biomarkers that are sensitive to the progression of disease, which might enhance the diagnostic algorithm and provide new drug targets, are now being identified from analysis of the blood and cerebrospinal fluid, as well as from neuroimaging and neurophysiology studies. In combination, these biomarkers might be sensitive to early therapeutic effects and would reduce our reliance on animal models, which have uncertain relevance to sporadic ALS in human beings. Such biomarkers might also resolve complexities of phenotypic heterogeneity in clinical trials. In this Review, we discuss the development of biomarkers in ALS and consider potential future directions for research

Item Type: Article
Schools and Departments: Brighton and Sussex Medical School > Clinical Medicine
Subjects: R Medicine > RC Internal medicine > RC0321 Neurosciences. Biological psychiatry. Neuropsychiatry > RC0346 Neurology. Diseases of the nervous system Including speech disorders
Related URLs:
Depositing User: Patricia Butler
Date Deposited: 14 Nov 2012 18:08
Last Modified: 14 Nov 2012 18:08
URI: http://sro.sussex.ac.uk/id/eprint/42514
📧 Request an update